Align Technology, Inc. (NASDAQ:ALGN) Shares Purchased by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. raised its holdings in Align Technology, Inc. (NASDAQ:ALGN) by 11.8% during the third quarter, HoldingsChannel.com reports. The firm owned 8,338 shares of the medical equipment provider’s stock after buying an additional 878 shares during the period. Landscape Capital Management L.L.C.’s holdings in Align Technology were worth $2,121,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. First Horizon Advisors Inc. boosted its stake in Align Technology by 16.2% during the 3rd quarter. First Horizon Advisors Inc. now owns 990 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 138 shares during the last quarter. Commerce Bank raised its stake in shares of Align Technology by 47.0% in the 3rd quarter. Commerce Bank now owns 3,381 shares of the medical equipment provider’s stock valued at $860,000 after purchasing an additional 1,081 shares in the last quarter. Prospera Private Wealth LLC acquired a new stake in shares of Align Technology in the 3rd quarter valued at about $114,000. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Align Technology during the third quarter worth about $742,000. Finally, Banque Cantonale Vaudoise grew its stake in Align Technology by 240.2% in the third quarter. Banque Cantonale Vaudoise now owns 6,909 shares of the medical equipment provider’s stock worth $1,757,000 after purchasing an additional 4,878 shares in the last quarter. 88.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ALGN has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Align Technology in a report on Monday, November 4th. Morgan Stanley dropped their price target on Align Technology from $310.00 to $280.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Evercore ISI decreased their price objective on shares of Align Technology from $270.00 to $250.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. StockNews.com raised shares of Align Technology from a “hold” rating to a “buy” rating in a report on Thursday, September 19th. Finally, Stifel Nicolaus decreased their price target on shares of Align Technology from $285.00 to $275.00 and set a “buy” rating for the company in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $276.38.

Align Technology Stock Up 2.0 %

Shares of NASDAQ:ALGN opened at $228.39 on Friday. Align Technology, Inc. has a fifty-two week low of $196.09 and a fifty-two week high of $335.40. The company has a market cap of $17.05 billion, a PE ratio of 38.97, a P/E/G ratio of 5.77 and a beta of 1.65. The company’s 50-day moving average price is $228.89 and its 200 day moving average price is $238.58.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.04. Align Technology had a return on equity of 13.99% and a net margin of 11.15%. The business had revenue of $977.87 million during the quarter, compared to the consensus estimate of $990.05 million. During the same period in the previous year, the firm posted $1.62 earnings per share. The business’s revenue was up 1.8% on a year-over-year basis. As a group, equities analysts anticipate that Align Technology, Inc. will post 7.45 EPS for the current year.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.